

# Yanis Boumber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1557/publications.pdf>

Version: 2024-02-01

42  
papers

2,763  
citations

279798

23  
h-index

289244

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4795  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. <i>Nature Genetics</i> , 2008, 40, 741-750.	21.4	554
2	Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells. <i>PLoS ONE</i> , 2008, 3, e2037.	2.5	215
3	Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets. <i>Clinical Cancer Research</i> , 2017, 23, 2143-2153.	7.0	215
4	Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). <i>Cancer</i> , 2020, 126, 260-270.	4.1	202
5	NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1171-1182.	4.9	192
6	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <i>Advances in Therapy</i> , 2019, 36, 2638-2678.	2.9	145
7	Musashi-2 (MSI2) supports TGF- $\beta$ 2 signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6955-6960.	7.1	120
8	Drug Sensitivity Prediction by CpG Island Methylation Profile in the NCI-60 Cancer Cell Line Panel. <i>Cancer Research</i> , 2007, 67, 11335-11343.	0.9	104
9	Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 823-829.	4.1	98
10	Chromatin Remodeling Is Required for Gene Reactivation after Decitabine-Mediated DNA Hypomethylation. <i>Cancer Research</i> , 2010, 70, 6968-6977.	0.9	81
11	Epigenetics in cancer: what's the future?. <i>Oncology</i> , 2011, 25, 220-6, 228.	0.5	76
12	RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis. <i>Cancer Research</i> , 2007, 67, 1997-2005.	0.9	72
13	An Sp1/Sp3 Binding Polymorphism Confers Methylation Protection. <i>PLoS Genetics</i> , 2008, 4, e1000162.	3.5	64
14	Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 4689-4693.	1.4	57
15	A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 2704-2714.	7.0	56
16	A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. <i>Leukemia</i> , 2012, 26, 2428-2431.	7.2	52
17	Anti- $\beta$ -adrenergic Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. <i>Cell Reports</i> , 2016, 16, 657-671.	6.4	47
18	Epigenetic Inactivation of Notch-Hes Pathway in Human B-Cell Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2013, 8, e61807.	2.5	44

#	ARTICLE	IF	CITATIONS
19	The convergent roles of NF- $\kappa$ B and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 374.	6.3	35
20	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. <i>Cancers</i> , 2021, 13, 3164.	3.7	35
21	DNA Methylation Profiles of Primary Colorectal Carcinoma and Matched Liver Metastasis. <i>PLoS ONE</i> , 2011, 6, e27889.	2.5	33
22	Recent Advances in Immunotherapy in Metastatic NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 239.	2.8	29
23	A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5120-5129.	7.0	28
24	Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review). <i>International Journal of Oncology</i> , 2022, 60, .	3.3	25
25	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 112.	2.8	23
26	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). <i>Cancers</i> , 2019, 11, 1297.	3.7	21
27	The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 285.	5.4	19
28	The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. <i>Future Oncology</i> , 2016, 12, 2713-2727.	2.4	18
29	Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC). <i>Oncogenesis</i> , 2021, 10, 29.	4.9	18
30	Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 576314.	2.8	17
31	Case report: reinitiating pembrolizumab treatment after small bowel perforation. <i>BMC Cancer</i> , 2019, 19, 379.	2.6	14
32	Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 947-952.	4.9	13
33	CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1749-1756.	6.4	13
34	Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?. <i>Cancer Biology and Therapy</i> , 2017, 18, 940-943.	3.4	7
35	Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2021, 13, 1370-1379.	1.4	7
36	Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression. <i>PLoS ONE</i> , 2021, 16, e0252132.	2.5	5

#	ARTICLE	IF	CITATIONS
37	INST OXâ€05â€024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. <i>Cancer Medicine</i> , 2017, 6, 2042-2051.	2.8	3
38	Miliary Adenocarcinoma of the Lung Responds to Gefitinib and Afatinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e95-e97.	1.1	3
39	An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion. <i>BMC Cancer</i> , 2019, 19, 614.	2.6	2
40	Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 3567-3567.	1.4	1
41	In Vitro Effects of the Combination of Idarubicin (IDA) with Suberoylanilide Hydroxamic Acid (SAHA) or Valproic Acid (VPA) in Leukemia Cell Lines.. <i>Blood</i> , 2004, 104, 1173-1173.	1.4	0
42	Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). <i>Blood</i> , 2011, 118, 1530-1530.	1.4	0